NexImmune, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 32.34 million compared to USD 62.51 million a year ago. Basic loss per share from continuing operations was USD 30.82 compared to USD 64.95 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.336 USD | -3.02% | -7.33% | +50.27% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+50.27% | 4.57M | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.71% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- NEXI Stock
- News NexImmune, Inc.
- NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023